1.
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
by Malfertheiner, Peter
Gut, 2012, Vol.61 (5), p.646-664
2.
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial
by Liou, Jyh-Ming, MD
The Lancet (British edition), 2016, Vol.388 (10058), p.2355-2365
3.
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy
by Zhang, Wei
Gut, 2015, Vol.64 (11), p.1715-1720
4.
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study
by Molina‐Infante, J.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (6), p.581-589
5.
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled...
by Fukase, Kazutoshi, MD
The Lancet (British edition), 2008, Vol.372 (9636), p.392-397
6.
Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma
by Essilfie, Ama-Tawiah
Thorax, 2015, Vol.70 (5), p.458-467
7.
8.
The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention
by Lee, Yi-Chia
Gut, 2013, Vol.62 (5), p.676-682
9.
Clinical trial: clarithromycin vs. levofloxacin in first‐line triple and sequential regimens for Helicobacter pylori eradication
by MOLINA‐INFANTE, J.
Alimentary pharmacology & therapeutics, 2010, Vol.31 (10), p.1077-1084
10.
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions
by Wong, Benjamin C Y
Gut, 2012, Vol.61 (6), p.812-818
11.
Review article: non‐bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori
by Gisbert, J. P.
Alimentary pharmacology & therapeutics, 2011, Vol.34 (6), p.604-617
12.
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough
by Gisbert, J. P.
Alimentary pharmacology & therapeutics, 2011, Vol.34 (11‐12), p.1255-1268
13.
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori
by Tsujimae, Masahiro
Digestion, 2016, Vol.94 (4), p.240-246
14.
Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori Infection
by Venerito, Marino
Digestion, 2013, Vol.88 (1), p.33-45
15.
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial
by Nienhuis, Willemien A, MD
The Lancet (British edition), 2010, Vol.375 (9715), p.664-672
16.
A trial of clarithromycin for the treatment of suboptimally controlled asthma
by Sutherland, E. Rand, MD, MPH
Journal of allergy and clinical immunology, 2010, Vol.126 (4), p.747-753
17.
Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment
by Mougari, Faiza
Expert review of anti-infective therapy, 2016, Vol.14 (12), p.1139-1154
18.
19.
Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori
by Cosme, A
Clinical microbiology and infection, 2013, Vol.19 (4), p.379-383
20.
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication
by Leung, W K
Gut, 2004, Vol.53 (9), p.1244-1249
